


Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT Date Submitted: January 25, 2005 (use as many sheets as necessary)				Complete if Known	
				Application Number	10/813,432
				Filing Date	03/31/2004
				First Named Inventor	Thomas E. WAGNER et al
				Group Art Unit	1646
				Examiner Name	Unassigned
				Attorney Docket Number	035879-0182
Sheet	1	of	1		



U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
BF	A1	2002/0168371		Awwad	11/14/2002	

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Office ³	Number ⁴	Kind Code ⁵ (if known)				
BF	A2	WO	2001/61017		Fondazione Centro San Raffaele Del Monte Tabor	08/23/2001		
BF	A3	WO	1998/10795		The Burnham Institute	03/19/1998		

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶

Examiner Signature	/Brandon Fetterolf/	Date Considered	10/02/2006
--------------------	---------------------	-----------------	------------


*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

 Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT Date Submitted: September 15, 2004 (Use as many sheets as necessary)		Complete if Known	
		Application Number	10/813,432
		Filing Date	03/31/2004
		First Named Inventor	Thomas E. Wagner
		Group Art Unit	1646
		Examiner Name	Unassigned
		Attorney Docket Number	035879-0182

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
BF	A1	6,180,084	B1	Ruoslahti et al.	01-30-2001	
↓	A2	6,296,832	B1	Ruoslahti et al.	10-02-2001	
↓	A3	2001/0049142	A1	Wagner et al.	12-06-2001	
↓	A4	6,491,894	B1	Ruoslahti et al.	12-10-2002	
BF	A5	6,528,481	B1	Burg et al.	03-04-2003	

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Office ³	Number ⁴	Kind Code ⁵ (if known)				

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶	
<div>BF</div> <div>↓</div> <div>BF</div>	A6	MAURO S. SANDRIN et al., "Gal(1,3)Gal, the Major Xenoantigen(s) Recognised in Pigs by Human Natural Antibodies", <i>Immunological Reviews</i> , 1994, No. 141, pp. 169-190.		
	A7	CHARLES J. LINK, JR. et al., "Eliciting Hyperacute Xenograft Response to Treat Human Cancer: α(1,3)Galactosyltransferase Gene Therapy", <i>Anticancer Research</i> , 18: (1998), pp. 2301-2308.		
	A8	U JÄGER et al., "Induction of complement attack on human cells by Gal(alpha 1,3)Gal xenoantigen expression as a gene therapy approach to cancer", <i>Gene Therapy</i> , 6, (1999), pp. 1073-1083.		

Examiner Signature	/Brandon Fetterolf/	Date Considered	10/02/2006
--------------------	---------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 18 if possible. ⁶ Applicant is to place a check mark here if English language translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT Date Submitted: September 15, 2004 (use as many sheets as necessary)				Application Number	10/813,432
				Filing Date	03/31/2004
				First Named Inventor	Thomas E. Wagner
				Group Art Unit	1646
				Examiner Name	Unassigned
Sheet	2	of	2	Attorney Docket Number	035879-0182

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.		T ⁶
BF ↓ ↓ ↓	A9	ERIC B. KMIEC, "Investigators have been searching for ways to add corrective genes to cells harboring defective genes. A better strategy might be to correct the defects", <i>American Scientist</i> , Volume 87, (1999), pp. 240-247.		
	A10	FLAVIO CURNIS et al., "Differential Binding of Drugs Containing the NGR Motif to CD13 Isoforms in Tumor Vessels, Epithelia, and Myeloid Cells", <i>Cancer Research</i> , 62, (February 1, 2002), pp. 867-874.		
	A11	SABINE ZITZMANN et al., "Arginine-Glycine-Aspartic Acid (RGD)-Peptide Binds to Both Tumor and Tumor-Endothelial Cells <i>in Vivo</i> ", <i>Cancer Research</i> , 62, (September 15, 2002), pp. 5139-5143.		
	A12	EDWARD FINGL et al., "The Pharmacological Basis of Therapeutics", Chapter 1, pp. 1-46.		
BF	A13	MASAKI FUJITA et al., "Sodium 1-(12-Hydroxy)octadecanyl Sulfate, an MMP2 Inhibitor, Isolated from a Tunicate of the Family Polyclinidae", <i>J. Nat. Prod.</i> , 65, (2002), pp. 1936-1938.		

Examiner Signature	/Brandon Fetterolf/	Date Considered	10/02/2006
--------------------	---------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.